QR12000 Compound Tablets in Patients with Moderate to Severe Essential Hypertension
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 810 participants.
Also called NCT06716970
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 810 participants
- Sponsor
- Wuhan Createrna Science and Technology Co., Ltd
- Registry
-
NCT06716970
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT06716970. Randomized; quadruple masking; primary purpose treatment. Start 2024-12-30 (anticipated); primary completion 2026-04-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- QR12000 Compound Tablets in Patients with Moderate to Severe Essential Hypertension
- Condition
- Essential Hypertension
- Intervention (Drug)
- QR12000 75mg
- Intervention (Drug)
- QR12000 75mg placebo
- Intervention (Drug)
- QR12000 150mg
- Intervention (Drug)
- QR12000 150mg placebo
- Intervention (Drug)
- Sacubitril/valsartan 200mg
- Intervention (Drug)
- Sacubitril/valsartan 200mg placebo
- Lead sponsor
- Wuhan Createrna Science and Technology Co., Ltd
Record details
- Record id
cardio:ct-nct06716970- Content hash
8761ca7f780b71779c03dc44eaff222e15604531db80edc2e599f4703c15942c